On the day, 1475611 shares were traded.
Ratios:
For a deeper understanding of Beam Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.89 and its Current Ratio is at 5.89. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Upgraded its rating to Overweight and sets its target price to $40 from $38 previously.
On December 15, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $35.
Jefferies Downgraded its Buy to Hold on December 08, 2023, whereas the target price for the stock was revised from $75 to $30.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 02 ’24 when Simon Amy sold 16,530 shares for $30.54 per share. The transaction valued at 504,851 led to the insider holds 70,060 shares of the business.
Evans John M. sold 18,102 shares of BEAM for $581,617 on Apr 01 ’24. The CEO now owns 1,058,343 shares after completing the transaction at $32.13 per share. On Apr 01 ’24, another insider, Simon Amy, who serves as the Chief Medical Officer of the company, sold 7,157 shares for $32.13 each. As a result, the insider received 229,954 and left with 86,590 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 5.56 while its Price-to-Book (P/B) ratio in mrq is 2.14.
Stock Price History:
Over the past 52 weeks, BEAM has reached a high of $49.50, while it has fallen to a 52-week low of $16.95.
Shares Statistics:
A total of 81.63M shares are outstanding, with a floating share count of 67.88M. Insiders hold about 16.88% of the company’s shares, while institutions hold 76.98% stake in the company.
Earnings Estimates
There are Atlassian Corporation different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $25.70, with high estimates of $5.52 and low estimates of $6.45.
Analysts are recommending an EPS of between $Technology and $Technology for the fiscal current year, implying an average EPS of $Healthcare.
